![\"\"](\"https:\/\/www.azuse.cloud\/wp-content\/uploads\/2020\/02\/antique-caduceus-300x258.jpg\")
<\/p>\n<\/p>\n
Post-traumatic stress disorder (PTSD) presents a health problem for which currently available treatments are modestly effective. Here is the report of the findings of a “randomized, double-blind, placebo-controlled, multi-site phase 3 clinical trial” to test the efficacy and safety of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for the treatment of patients with severe PTSD, including those with common comorbidities.<\/p>\n
MDMA, also known as Ecstasy or Molly, increases levels of several chemicals in the brain, including serotonin, dopamine, and norepinephrine. It alters one’s mood to feel closer and more connected to others. Users get a sense of euphoria and a boost in energy.<\/p>\n
MDMA is largely known as a club drug<\/em><\/strong><\/p>\n By Julia Musto<\/p>\n MDMA-assisted therapy has been able to aid people with severe PTSD, according to researchers.<\/p>\n In an updated study first published in May in the journal Nature Medicine, authors from New York University, UC San Francisco and led by San Jose, California’s nonprofit MAPS (Multidisciplinary Association for Psychedelic Studies), patients with severe PTSD \u2013 including common comorbidities \u2013 were given three doses of MDMA, or “ecstasy,” in conjunction with manualized therapy over a period of 18 weeks.<\/p>\n The double-blind study’s participants were randomized to receive manualized therapy with the psychedelic or with placebo, combined with three preparatory and nine integrative therapy sessions.<\/p>\n PTSD symptoms were measured using the Clinician-Administered PTSD Scale, and functional impairment was measured using the Sheehan Disability Scale. Both were assessed at the baseline of the study and two months following the last experimental session.<\/p>\n Suicidality and adverse events were also tracked.<\/p>\n One hundred thirty-one patients were enrolled in the study, 91 were confirmed for randomization across the U.S., Canada and Israel, 56 were randomized to MDMA and 44 received placebo.<\/p>\n The group found that there was a “significant and robust attenuation of PTSD symptoms and functional impairment,”<\/strong> respectively.<\/p><\/blockquote>\n Fox News<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"